| Identification | Back Directory | [Name]
DM1-Sme | [CAS]
138148-68-2 | [Synonyms]
DM1-Sme
CS-2715
DM1-SSMe
AP3 Intermidate 2
MaytansinoidDM4Impurity6
1H-Inden-2-ol,1-amino-2,3-dihydro-,(1R,4S)-
N2'-Deacetyl-N2'-[3-(methyldithio)-1-oxopropyl]maytansine
Maytansine, N2'-deacetyl-N2'-[3-(methyldithio)-1-oxopropyl]-
4,24-Dioxa-9,22-diazatetracyclo[19.3.1.1 10,14.03,5]hexacosane,maytansine deriv.
maytansinoid derivative with ADC linker. Maytansine or mertansine or emtansine derivative
DM1-SME; DM1-SSME; MAYTANSINOID DERIVATIVE WITH ADC LINKER. MAYTANSINE OR MERTANSINE OR EMTANSINE DERIVATIVE; N2'-DEACETYL-N2'-[3-(METHYLDITHIO)-1-OXOPROPYL]MAYTANSINE.
(14S,16S,32S,33S,2R,4S,10E,12E,14R)-86-Chloro-14-hydroxy-85,14-dimethoxy-33,2,7,10-tetramethyl-12,6-dioxo-7-aza-1(6,4)-oxazinana-3(2,3)-oxirana-8(1,3)-benzenacyclotetradecaphane-10,12-dien-4-yl N-methyl-N-(3-(methyldisulfaneyl)propanoyl)-L-alaninate | [Molecular Formula]
C36H50ClN3O10S2 | [MOL File]
138148-68-2.mol | [Molecular Weight]
784.38 |
| Chemical Properties | Back Directory | [Boiling point ]
957.1±65.0 °C(Predicted) | [density ]
1.34±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:12.0(Max Conc. mg/mL);15.3(Max Conc. mM)
DMF:16.0(Max Conc. mg/mL);20.4(Max Conc. mM)
DMF:PBS (pH 7.2) (1:5):0.16(Max Conc. mg/mL);0.2(Max Conc. mM) | [form ]
A crystalline solid | [pka]
9.82±0.70(Predicted) | [color ]
Off-white to light yellow | [InChIKey]
ZLUUPZXOPGORNG-PGOVPJOUNA-N |
| Hazard Information | Back Directory | [Uses]
DM1-SMe is an unconjugated form of the Maytansinoid in IMGN901. DM1-SMe is the microtubule inhibitor and can be used as the ADC cytotoxin[1]. | [in vivo]
DM1-SMe (15 mg/kg in form of IMGN901, iv, three times a week for 6 weeks) exhibits antitumor efficacy in xenograft mouse models[1]. | Animal Model: | PPTP solid tumor xenograft mouse model[1]. | | Dosage: | 15 mg/kg in form of IMGN901 | | Administration: | iv, three times a week for 6 weeks | | Result: | Inhibited tumor growth. |
| [IC 50]
Maytansinoids | [storage]
Store at -20°C | [References]
[1] Wood AC, et al. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013;60(11):1860-1867. DOI:10.1002/pbc.24647
[2] Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41(1):98-107. DOI:10.1021/ar700108g |
|
|